TAT-PEG-PLGA coated manganese-doped silicon dioxide drug-loaded nanoparticles as well as preparation and application thereof
Through TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles, the problems of low drug intake efficiency and difficulty in release control in tumor treatment are solved, and efficient drug delivery and release control is achieved, which significantly improves the problem of nanomaterials. The therapeutic effect.
Patent Information
- Application Number
- CN202411013763.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-12
AI Technical Summary
The existing nanomaterials have problems such as low drug intake efficiency, limited drug loading capacity and difficult drug release in tumor treatment, resulting in poor treatment results.
Manganese-doped silica drug-loaded nanoparticles wrapped with TAT-PEG-PLGA, improve the cellular uptake efficiency and stability of nanoparticles through TAT cell permeability peptide and PEG modification, and control the mechanical strength and biodegradability of PLGA. Drug release.
It improves the uptake efficiency of nanomaterials in tumor cells, can load a variety of drugs, and achieves precise control of drug release, significantly enhances the therapeutic effect and reduces the toxicity to normal cells.
Smart Images

Figure CN118924701A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of nano drug carriers, and in particular to TAT-PEG-PLGA-wrapped manganese-doped silica drug-carrying nanoparticles and preparation and application thereof. Background Art
[0002] With the rapid development of nanotechnology, nanomaterials have shown great potential in the field of tumor treatment. Nanomaterials have unique physical and chemical properties, such as high specific surface area, controllable size and surface functionalization, making them ideal drug carriers. However, existing nanomaterials still face some challenges in tumor treatment, such as low drug uptake efficiency, limited drug loading capacity, and difficult to control drug release.
[0003] First, the nanomaterials currently used for tumor treatment have low uptake efficiency in tumor cells, resulting in insufficient concentration of drugs at the target site and poor therapeutic effect. Therefore, improving the uptake efficiency of nanomaterials in tumor cells is one of the keys to improving the therapeutic effect. Secondly, existing nanomaterials can usually only load a single type of drug, which limits their application in combined therapy. Combined therapy can enhance the therapeutic effect and reduce the side effects of a single drug through the synergistic effect of multiple drugs. Therefore, the development of nanomaterials that can load different types of drugs is of great significance for improving the therapeutic effect of tumors. In addition, the release rate and time of drugs during treatment have an important influence on the therapeutic effect. Existing nanomaterials often find it difficult to achieve precise control of drug release, resulting in uneven release of drugs during treatment, thereby affecting the therapeutic effect. Therefore, nanomaterials with mechanical strength and the ability to control drug release have important application value in tumor treatment. Summary of the invention
[0004] Based on this, the present invention proposes a TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticle, which has a high cellular uptake efficiency on various tumors, can load a variety of drugs, and has mechanical strength and the ability to control drug release.
[0005] Part I:
[0006] A TAT-PEG-PLGA-coated manganese-doped silica drug-loaded nanoparticle, wherein the surface of the manganese-doped silica is coated with TAT-PEG-PLGA; wherein TAT is a cell-penetrating peptide with a sequence number of GRKKRRQRRRPQ, PEG is polyethylene glycol, and PLGA is a polylactic acid-glycolic acid copolymer; and the structure of the TAT-PEG-PLGA is that TAT is connected to PLGA via PEG.
[0007] PLGA is a widely used biodegradable polymer with good biocompatibility and biodegradability. It can be used as the skeleton structure of nanoparticles, has high mechanical strength, and has the ability to control drug release. PEG is a hydrophilic polymer used to improve the water solubility and biocompatibility of nanoparticles. PEG-modified nanoparticles have "invisible" properties and can evade clearance by the immune system, helping nanoparticles to aggregate at tumor sites, thereby prolonging blood circulation time. In addition, PEG can reduce the nonspecific adsorption of nanoparticles in the body and increase their stability and targeting. TAT is the transduction domain peptide sequence of the HIV-1 virus, which has high efficiency in penetrating the membrane. Its main function is to improve the efficiency of cell uptake of nanoparticles, especially for cells that are difficult to enter.
[0008] In the present invention, drugs can be loaded in manganese-doped silica, and TAT-PEG-PLGA is modified on the surface of manganese-doped silica, so that nanoparticles can be effectively taken up by cells, thereby improving the therapeutic effect of the drugs.
[0009] As a preferred solution, the manganese content in the manganese-doped silica is 15-30 wt %. The manganese-doped silica with this manganese content can achieve both high drug loading and high mechanical strength.
[0010] As a preferred solution, the particle size of the manganese-doped silica is 50-120 nm. More preferably, the particle size of the manganese-doped silica is 70-80 nm. Nanoparticles of this particle size can maintain high mechanical strength while ensuring drug loading.
[0011] Part II:
[0012] A method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles as described in the first part comprises the following steps:
[0013] Dissolve hexadecyltrimethylammonium p-toluenesulfonate and triethanolamine, mix well, stir at 70-90°C for 0.8-2h, then add tetraethyl orthosilicate, stir at 70-90°C for 2-3h to obtain a solid precipitate;
[0014] The solid precipitate is dried at 50-60° C. for 12-24 h, and then calcined at 550-600° C. for 5-8 h to obtain mesoporous silica nanospheres;
[0015] The mesoporous silica nanospheres are mixed with manganese sulfate monohydrate and disodium maleate in water, and reacted under hydrothermal conditions of 180-200° C. for 5-6 hours to obtain manganese-doped silica;
[0016] Mixing the drug and the manganese-doped silica in a solvent, stirring for 12-24 hours, to obtain manganese-doped silica drug-loaded nanoparticles;
[0017] The manganese-doped silica drug-loaded nanoparticles and TAT-PEG-PLGA are dissolved in dichloromethane at a mass ratio of (3-5):1 to obtain an oil phase mixture; 1-4wt% polyvinyl alcohol is added to the oil phase mixture and stirred for 1-2h to obtain TAT-PEG-PLGA-wrapped manganese-doped silica drug-loaded nanoparticles.
[0018] In the present invention, mesoporous silica nanospheres are first synthesized, and then manganese is doped into the silica to convert part of the silica into manganese orthosilicate, and at the same time, the non-hollow structure inside the mesoporous silica nanospheres is converted into a hollow structure, which can significantly increase the drug loading amount; then the manganese-doped silica is mixed with the drug to load the drug, and finally TAT-PEG-PLGA is wrapped on the outer surface to obtain TAT-PEG-PLGA-wrapped manganese-doped silica drug-loaded nanoparticles.
[0019] As a preferred embodiment, the mass ratio of hexadecyltrimethylammonium toluenesulfonate, triethanolamine, and tetraethyl orthosilicate is (4-5): (1-1.5): (35-40). More preferably, the mass ratio of hexadecyltrimethylammonium toluenesulfonate, triethanolamine, and tetraethyl orthosilicate is 5:1:36; adjusting the ratio of hexadecyltrimethylammonium toluenesulfonate, triethanolamine, and tetraethyl orthosilicate and the reaction conditions can control the particle size of the mesoporous silica nanospheres to be between 50-120 nm. Nanospheres with this particle size can ensure the drug loading amount, and in the subsequent manganese doping reaction step, it will not be difficult to effectively dope manganese due to too small a particle size, or the shell will not break due to too large a particle size.
[0020] As a preferred solution, the mesoporous silica nanospheres have conical pores with a pore diameter of 2.5-3 nm. The 2.5-3 nm conical pores can effectively accommodate manganese ions, and the interior is not a hollow structure, ensuring that the overall structure is not easily broken in the subsequent manganese doping reaction step.
[0021] As a preferred solution, the pore volume of the mesoporous silica nanospheres is not less than 1.4 ml / g. High pore volume can effectively improve drug loading efficiency.
[0022] As a preferred embodiment, the mass ratio of the mesoporous silica nanospheres, manganese sulfate monohydrate, and disodium maleate is (2-3):(6-9):(6-12). More preferably, the mass ratio of the mesoporous silica nanospheres, manganese sulfate monohydrate, and disodium maleate is 2:6:7; the manganese content of the manganese-doped silica can be controlled by adjusting the ratio of the silica nanospheres, manganese sulfate monohydrate, and disodium maleate and the reaction conditions.
[0023] As a preferred embodiment, the drug includes at least one of doxorubicin, paclitaxel, quercetin, and IR-780 iodide.
[0024] Part III:
[0025] The first part describes the application of TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles in the treatment of tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Schematic diagram of the synthesis of TAT-PEG-PLGA;
[0027] Figure 2 is the NMR spectrum of TAT-PEG-PLGA;
[0028] Figure 3 is a transmission electron microscope image of SMSN in Example 5;
[0029] Figure 4 is a transmission electron microscopy image of Mn-SMSN in Example 5;
[0030] Figure 5 is the UV absorption spectrum of TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760 in Example 5;
[0031] Figure 6 It is a transmission electron microscopy image of TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760 in Example 5;
[0032] Figure 7 This is a graph showing the results of a CCK8 experiment on PC3 human prostate cancer cells in Example 8;
[0033] Figure 8 This is a graph showing the results of a CCK8 experiment on RWPE-1 human prostate epithelial cells in Example 9;
[0034] Fig. 9 This is a graph showing the results of a CCK8 experiment on 7860 human renal cancer cells in Example 10;
[0035] Fig.10 This is a graph showing the results of a CCK8 experiment on HK-2 human kidney epithelial cells in Example 11;
[0036] Fig.11 This is a graph showing the drug release rate experimental results in Example 12. DETAILED DESCRIPTION
[0037] In order to further understand the present invention, the present invention is described in detail below in conjunction with the embodiments. However, it should be noted that the embodiments do not limit the scope of protection claimed for the present invention.
[0038] A TAT-PEG-PLGA-wrapped manganese-doped silica drug-loaded nanoparticle (TAT-PEG-PLGA@Mn-SMSN), wherein the surface of manganese-doped silica (Mn-SMSN) is wrapped with TAT-PEG-PLGA; wherein TAT is a cell-penetrating peptide with a sequence number of GRKKRRQRRRPQ, PEG is polyethylene glycol, and PLGA is a polylactic acid-glycolic acid copolymer; the structure of the TAT-PEG-PLGA is that TAT is connected to PLGA via PEG; the particle size of the manganese-doped silica (Mn-SMSN) is 50-120 nm, and the manganese content is 15-30 wt%.
[0039] A method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN) comprises the following steps:
[0040] Mix hexadecyltrimethylammonium p-toluenesulfonate and triethanolamine in water, stir at 70-90° C. for 0.8-2 h, then add tetraethyl orthosilicate, stir at 70-90° C. for 2-3 h to obtain a solid precipitate, wherein the mass ratio of hexadecyltrimethylammonium p-toluenesulfonate, triethanolamine, and tetraethyl orthosilicate is (4-5):(1-1.5):(35-40);
[0041] The solid precipitate is dried at 50-60° C. for 12-24 h, and then calcined at 550-600° C. for 5-8 h to obtain mesoporous silica nanospheres;
[0042] The mesoporous silica nanospheres are mixed with manganese sulfate monohydrate and disodium maleate in water in a mass ratio of (2-3):(6-9):(6-12), and reacted under hydrothermal conditions of 180-200° C. for 5-6 hours to obtain manganese-doped silica;
[0043] Mixing the drug and the manganese-doped silica in a solvent, stirring for 12-24 hours, to obtain manganese-doped silica drug-loaded nanoparticles;
[0044] The manganese-doped silica drug-loaded nanoparticles and TAT-PEG-PLGA are dissolved in dichloromethane at a mass ratio of (3-5):1 to obtain an oil phase mixture; 1-4wt% polyvinyl alcohol is added to the oil phase mixture and stirred for 1-2h to obtain TAT-PEG-PLGA-wrapped manganese-doped silica drug-loaded nanoparticles.
[0045] Application of TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN) in the treatment of tumors. In the embodiments of the present invention, prostate cancer cells and renal cancer cells are taken as examples. The drugs used are DOX and IR-780, which are used as chemotherapeutic drugs and photothermal therapeutic agents, respectively, to achieve better therapeutic effects through synergistic effects.
[0046] Example 1
[0047] A TAT-PEG-PLGA-wrapped manganese-doped silica drug-loaded nanoparticle (TAT-PEG-PLGA@Mn-SMSN), wherein the surface of manganese-doped silica (Mn-SMSN) is wrapped with TAT-PEG-PLGA; wherein TAT is a cell-penetrating peptide with a sequence number of GRKKRRQRRRPQ, PEG is polyethylene glycol, and PLGA is a polylactic acid-glycolic acid copolymer; the structure of the TAT-PEG-PLGA is that TAT is connected to PLGA via PEG; the particle size of the manganese-doped silica (Mn-SMSN) is 75 nm, and the manganese content is 25 wt%.
[0048] Example 2
[0049] A TAT-PEG-PLGA-wrapped manganese-doped silica drug-loaded nanoparticle (TAT-PEG-PLGA@Mn-SMSN), wherein the surface of manganese-doped silica (Mn-SMSN) is wrapped with TAT-PEG-PLGA; wherein TAT is a cell-penetrating peptide with a sequence number of GRKKRRQRRRPQ, PEG is polyethylene glycol, and PLGA is a polylactic acid-glycolic acid copolymer; the structure of the TAT-PEG-PLGA is that TAT is connected to PLGA via PEG; the particle size of the manganese-doped silica (Mn-SMSN) is 50 nm, and the manganese content is 15 wt%.
[0050] Example 3
[0051] A TAT-PEG-PLGA-wrapped manganese-doped silica drug-loaded nanoparticle (TAT-PEG-PLGA@Mn-SMSN), wherein the surface of manganese-doped silica (Mn-SMSN) is wrapped with TAT-PEG-PLGA; wherein TAT is a cell-penetrating peptide with a sequence number of GRKKRRQRRRPQ, PEG is polyethylene glycol, and PLGA is a polylactic acid-glycolic acid copolymer; the structure of the TAT-PEG-PLGA is that TAT is connected to PLGA via PEG; the particle size of the manganese-doped silica (Mn-SMSN) is 120 nm, and the manganese content is 30 wt%.
[0052] Example 4
[0053] A TAT-PEG-PLGA-wrapped manganese-doped silica drug-loaded nanoparticle (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760), wherein the surface of manganese-doped silica (Mn-SMSN) is wrapped with TAT-PEG-PLGA; wherein TAT is a cell-penetrating peptide with a sequence number of GRKKRRQRRRPQ, PEG is polyethylene glycol, and PLGA is a polylactic acid-glycolic acid copolymer; the structure of the TAT-PEG-PLGA is that TAT is connected to PLGA via PEG; the particle size of the manganese-doped silica (Mn-SMSN) is 70-80 nm, and the manganese content is 25 wt%; and the drugs loaded in the manganese-doped silica (Mn-SMSN) are doxorubicin (DOX) and IR-760.
[0054] Figure 1 Schematic diagram of the synthesis of TAT-PEG-PLGA. Figure 2 This is the NMR spectrum of TAT-PEG-PLGA, and the characteristic peak of TAT polypeptide appears, indicating that TAT is connected to PLGA through PEG and TAT-PEG-PLGA is successfully synthesized.
[0055] Example 5
[0056] The preparation method of TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760) in Example 4 comprises the following steps:
[0057] Hexadecyltrimethylammonium p-toluenesulfonate and triethanolamine were uniformly mixed in water, stirred at 80°C for 1 hour, and then tetraethyl orthosilicate was added, and stirred at 80°C for 2 hours to obtain a solid precipitate, wherein the mass ratio of hexadecyltrimethylammonium p-toluenesulfonate, triethanolamine, and tetraethyl orthosilicate was 5:1:36;
[0058] The solid precipitate was dried at 60° C. for 24 h and then calcined at 550° C. for 6 h to obtain mesoporous silica nanospheres (SMSN);
[0059] The mesoporous silica nanospheres, manganese sulfate monohydrate and disodium maleate are uniformly mixed in water at a mass ratio of 2:6:7, and reacted under hydrothermal conditions at 180° C. for 6 hours to obtain manganese-doped silica (Mn-SMSN);
[0060] Doxorubicin (DOX), IR-760 and the manganese-doped silica were uniformly mixed in a solvent at a mass ratio of 1:1:2, and stirred for 24 hours to obtain manganese-doped silica drug-loaded nanoparticles (Mn-SMSN@DOX-IR-760);
[0061] The manganese-doped silica drug-loaded nanoparticles and TAT-PEG-PLGA were dissolved in dichloromethane at a mass ratio of 4:1 to obtain an oil phase mixture; 3 wt % polyvinyl alcohol was added to the oil phase mixture and stirred for 1 h to obtain TAT-PEG-PLGA-coated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760).
[0062] Figure 3 This is a transmission electron microscopy image of mesoporous silica nanospheres (SMSN). Figure 4 This is a transmission electron microscopy image of manganese-doped silica (Mn-SMSN). It can be seen that after manganese doping, the mesoporous silica nanospheres are transformed from a non-hollow structure to a hollow structure; Figure 5 This is the UV absorption spectrum of TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760. Figure 6 This is a transmission electron microscopy image of TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760). The characteristic peaks of DOX and IR-760 appear in the ultraviolet absorption spectrum, indicating that the nanoparticles have successfully loaded multiple drugs.
[0063] Example 6
[0064] A method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760) comprises the following steps:
[0065] Mix hexadecyltrimethylammonium p-toluenesulfonate and triethanolamine in water, stir at 70°C for 2h, then add tetraethyl orthosilicate, stir at 70°C for 3h to obtain a solid precipitate, wherein the mass ratio of hexadecyltrimethylammonium p-toluenesulfonate, triethanolamine and tetraethyl orthosilicate is 4:1.5:40;
[0066] The solid precipitate was dried at 50°C for 12 h and then calcined at 600°C for 5 h to obtain mesoporous silica nanospheres (SMSN);
[0067] The mesoporous silica nanospheres, manganese sulfate monohydrate and disodium maleate are uniformly mixed in water at a mass ratio of 2:9:6, and reacted under hydrothermal conditions at 200° C. for 5 hours to obtain manganese-doped silica (Mn-SMSN);
[0068] Doxorubicin (DOX), IR-760 and the manganese-doped silica were uniformly mixed in a solvent at a mass ratio of 1:1:2, and stirred for 12 hours to obtain manganese-doped silica drug-loaded nanoparticles (Mn-SMSN@DOX-IR-760);
[0069] The manganese-doped silica drug-loaded nanoparticles and TAT-PEG-PLGA were dissolved in dichloromethane at a mass ratio of 3:1 to obtain an oil phase mixture; 1 wt % polyvinyl alcohol was added to the oil phase mixture and stirred for 1 h to obtain TAT-PEG-PLGA-coated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760).
[0070] Example 7
[0071] A method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760) comprises the following steps:
[0072] Hexadecyltrimethylammonium p-toluenesulfonate and triethanolamine were uniformly mixed in water, stirred at 90°C for 0.8h, and then tetraethyl orthosilicate was added, and stirred at 90°C for 2h to obtain a solid precipitate, wherein the mass ratio of hexadecyltrimethylammonium p-toluenesulfonate, triethanolamine, and tetraethyl orthosilicate was 5:1.2:35;
[0073] The solid precipitate was dried at 55° C. for 18 h and then calcined at 580° C. for 8 h to obtain mesoporous silica nanospheres (SMSN);
[0074] The mesoporous silica nanospheres, manganese sulfate monohydrate and disodium maleate are uniformly mixed in water at a mass ratio of 3:7:12, and reacted under hydrothermal conditions at 190° C. for 5.5 h to obtain manganese-doped silica (Mn-SMSN);
[0075] Doxorubicin (DOX), IR-760 and the manganese-doped silica were uniformly mixed in a solvent at a mass ratio of 1:1:2, and stirred for 20 hours to obtain manganese-doped silica drug-loaded nanoparticles (Mn-SMSN@DOX-IR-760);
[0076] The manganese-doped silica drug-loaded nanoparticles and TAT-PEG-PLGA were dissolved in dichloromethane at a mass ratio of 5:1 to obtain an oil phase mixture; 4 wt % polyvinyl alcohol was added to the oil phase mixture and stirred for 2 h to obtain TAT-PEG-PLGA-coated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760).
[0077] Example 8
[0078] CCK8 experiment of TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760) in Example 4.
[0079] The prepared PC3 human prostate cancer cell suspension was inoculated into a 96-well culture plate, and DOX, manganese-doped silica drug-loaded nanoparticles (Mn-SMSN@DOX-IR-760), and TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760) were added according to the group, and the culture plate was cultured in an incubator (37°C, 5% CO2) for 48 hours. DOX was used as a positive control group. 10 μL of CCK8 solution was added to each well; the culture plate was incubated in the incubator for 2 hours; and the absorbance at 450 nm was measured using an ELISA reader.
[0080] The results are as follows Figure 7 As shown in the data, the half inhibitory concentration (IC50) value of TAT-PEG-PLGA-encapsulated manganese-doped silica-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-780) on PC3 human prostate cancer cells was significantly lower than that of the single drug (DOX) and manganese-doped silica-loaded nanoparticles (Mn-SMSN@DOX-IR-780), indicating that the combination of PEG's targeted modification and TAT's efficient membrane penetration ability can more efficiently deliver drugs to tumor cells, thereby significantly enhancing the inhibitory effect of DOX.
[0081] Example 9
[0082] The PC3 human prostate cancer cells in Example 8 were replaced with RWPE-1 human prostate epithelial cells, and the other steps were exactly the same.
[0083] The results are as follows Figure 8 As shown in the figure, the half inhibitory concentration (IC50) value of TAT-PEG-PLGA-encapsulated manganese-doped silica-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-780) on RWPE-1 human prostate epithelial cells was significantly higher than that of the simple drug (DOX) and manganese-doped silica-loaded nanoparticles (Mn-SMSN@DOX-IR-780), indicating that the targeted modification of PEG effectively reduced the toxicity of nanoparticles to normal cells.
[0084] Example 10
[0085] The PC3 human prostate cancer cells in Example 8 were replaced with 7860 human kidney cancer cells, and the other steps were exactly the same.
[0086] The results are as follows Fig. 9 As shown in the figure, the half inhibitory concentration (IC50) value of TAT-PEG-PLGA-encapsulated manganese-doped silica-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-780) on 7860 human renal cancer cells was significantly lower than that of the simple drug (DOX) and manganese-doped silica-loaded nanoparticles (Mn-SMSN@DOX-IR-780), indicating that the combination of PEG's targeted modification and TAT's efficient membrane penetration ability can more efficiently deliver drugs to tumor cells, thereby significantly enhancing the inhibitory effect of DOX.
[0087] Embodiment 11
[0088] The PC3 human prostate cancer cells in Example 8 were replaced with HK-2 human kidney epithelial cells, and the other steps were exactly the same.
[0089] The results are as follows Fig.10 As shown in the figure, the half inhibitory concentration (IC50) value of TAT-PEG-PLGA-encapsulated manganese-doped silica-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-780) on HK-2 human renal epithelial cells was significantly higher than that of the simple drug (DOX) and manganese-doped silica-loaded nanoparticles (Mn-SMSN@DOX-IR-780), indicating that the targeted modification of PEG effectively reduced the toxicity of nanoparticles to normal cells.
[0090] The CCK8 experimental results of Examples 8-11 show that TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-780), under the combination of targeted modification of PEG and efficient membrane penetration ability of TAT, can not only enhance the inhibitory effect of drugs on tumor cells, but also significantly reduce the toxicity of drugs to normal cells, thereby improving the selectivity and safety of drugs.
[0091] Example 12
[0092] The controlled drug release ability experiment of manganese-doped silica drug-loaded nanoparticles (Mn-SMSN@DOX-IR-760) and TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-760) in Example 5.
[0093] The drug release of the nanoparticles was tested in vitro under a simulated tumor microenvironment (pH 4.5, 10 mM glutathione (GSH)) and a normal cell environment (pH 7.4), and the ultraviolet absorption of DOX was detected at 488 nm by an ELISA instrument to determine the drug release.
[0094] The results are as follows Fig.11 As shown in the figure, in the normal cell environment, both drugs have a lower release rate; in the tumor microenvironment, manganese-doped silica-loaded nanoparticles (Mn-SMSN@DOX-IR-760) have a tumor microenvironment-responsive release, and TAT-PEG-PLGA-encapsulated drug-loaded nanoparticles (TAT-PEG-PLGA@Mn-SMSN@DOX-IR-780) have higher mechanical strength and can control drug release more slowly, avoiding premature release of drugs in the systemic circulation process and causing side effects.
[0095] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. The present invention is not limited to the treatment of renal cancer cells and prostate cancer cells, but also has application effects on other cancer cells; the loaded drugs are not limited to adriamycin and IR-780, but can also be used to load multiple drugs. For those of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention.
Claims
1. A TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticle, characterized in that: The surface of manganese-doped silica is wrapped by TAT-PEG-PLGA; wherein TAT is a cell-penetrating peptide with a sequence number of GRKKRRQRRRPQ, PEG is polyethylene glycol, and PLGA is a polylactic acid-glycolic acid copolymer; the structure of the TAT-PEG-PLGA is that TAT is connected to PLGA via PEG.
2. The TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles according to claim 1, characterized in that: The manganese content in the manganese-doped silicon dioxide is 15-30 wt %.
3. The TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles according to claim 1, characterized in that: The particle size of the manganese-doped silicon dioxide is 50-120 nm.
4. A method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles according to any one of claims 1 to 3, characterized in that: The steps include: Dissolve hexadecyltrimethylammonium p-toluenesulfonate and triethanolamine, mix well, stir at 70-90°C for 0.8-2h, then add tetraethyl orthosilicate, stir at 70-90°C for 2-3h to obtain a solid precipitate; The solid precipitate is dried at 50-60° C. for 12-24 h, and then calcined at 550-600° C. for 5-8 h to obtain mesoporous silica nanospheres; The mesoporous silica nanospheres are mixed with manganese sulfate monohydrate and disodium maleate in water, and reacted under hydrothermal conditions of 180-200° C. for 5-6 hours to obtain manganese-doped silica; Mixing the drug and the manganese-doped silica in a solvent, stirring for 12-24 hours, to obtain manganese-doped silica drug-loaded nanoparticles; The manganese-doped silica drug-loaded nanoparticles and TAT-PEG-PLGA are dissolved in dichloromethane at a mass ratio of (3-5):1 to obtain an oil phase mixture; 1-4wt% polyvinyl alcohol is added to the oil phase mixture and stirred for 1-2h to obtain TAT-PEG-PLGA-wrapped manganese-doped silica drug-loaded nanoparticles.
5. The method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles according to claim 4, characterized in that: The mass ratio of the hexadecyltrimethylammonium p-toluenesulfonate, triethanolamine and tetraethyl orthosilicate is (4-5):(1-1.5):(35-40).
6. The method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles according to claim 5, characterized in that: The mesoporous silica nanospheres have conical pores with a pore diameter of 2.5-3 nm.
7. The method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles according to claim 5, characterized in that: The pore volume of the mesoporous silica nanospheres is not less than 1.4 ml / g.
8. The method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles according to claim 4, characterized in that: The mass ratio of the mesoporous silica nanospheres, manganese sulfate monohydrate and disodium maleate is (2-3):(6-9):(6-12).
9. The method for preparing TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles according to claim 4, characterized in that: The drug includes at least one of doxorubicin, paclitaxel, quercetin, and IR-780 iodide.
10. Use of the TAT-PEG-PLGA-encapsulated manganese-doped silica drug-loaded nanoparticles according to any one of claims 1 to 3 in treating tumors.
